Migraine affects around 10 million people in the UK and often runs in families. While there is not a single “migraine gene,” research indicates that multiple genetic factors can contribute to heightened sensitivity of nerve cells to triggers such as light and sound. Recent reporting highlights the emergence of new drug treatments that aim to reduce this underlying sensitivity and prevent debilitating migraine attacks within weeks, according to claims discussed by outlets covering the issue.
The articles also raise concerns about patient access to these therapies, pointing to barriers that limit widespread availability. However, the coverage does not specify the precise regulatory or prescribing mechanisms involved. Overall, the sources agree on the scale of migraine’s impact, the familial pattern of the condition, and the current scientific understanding that nerve-cell sensitivity plays an important role in migraine biology, forming the basis for developing targeted medications.
